It looks like we’ll have time to get the H1/26 report out before the next offering is needed, so if growth in clinical use continues well (and why wouldn’t it), the share price probably won’t be this low, considering the potential offering.
Will there be an Inderes interview with the CEO?
If so, I’d be most interested in the outlook on how investment cash flow will develop (hopefully decrease).